ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nanomaterial-Based Adjuvants Vaccine Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-4M9386
Home | Market Reports | Health| Pharmacy
Global Nanomaterial Based Adjuvants Vaccine Market Insights and Forecast to 2028
BUY CHAPTERS

Global Nanomaterial-Based Adjuvants Vaccine Market Research Report 2025

Code: QYRE-Auto-4M9386
Report
March 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline Biologicals
Merck
Pfizer Inc
Novartis
Moderna, Inc
Emergent Biosolutions
Sanofi
Jiangsu Recbio Technology

Nanomaterial-Based Adjuvants Vaccine Market Size

The global market for Nanomaterial-Based Adjuvants Vaccine was valued at US$ 326970 million in the year 2024 and is projected to reach a revised size of US$ 616850 million by 2031, growing at a CAGR of 9.6% during the forecast period.

Nanomaterial-Based Adjuvants Vaccine Market

Nanomaterial-Based Adjuvants Vaccine Market

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.
Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.
Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Nanomaterial-Based Adjuvants Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanomaterial-Based Adjuvants Vaccine.
The Nanomaterial-Based Adjuvants Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nanomaterial-Based Adjuvants Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanomaterial-Based Adjuvants Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Nanomaterial-Based Adjuvants Vaccine Market Report

Report Metric Details
Report Name Nanomaterial-Based Adjuvants Vaccine Market
Accounted market size in year US$ 326970 million
Forecasted market size in 2031 US$ 616850 million
CAGR 9.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, Jiangsu Recbio Technology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Nanomaterial-Based Adjuvants Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Nanomaterial-Based Adjuvants Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Nanomaterial-Based Adjuvants Vaccine Market growing?

Ans: The Nanomaterial-Based Adjuvants Vaccine Market witnessing a CAGR of 9.6% during the forecast period 2025-2031.

What is the Nanomaterial-Based Adjuvants Vaccine Market size in 2031?

Ans: The Nanomaterial-Based Adjuvants Vaccine Market size in 2031 will be US$ 616850 million.

What is the market share of major companies in Nanomaterial-Based Adjuvants Vaccine Market?

Ans: Global top 3 companies hold a share over 80%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by region?

Ans: North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by type?

Ans: In terms of product, Lipidosome is the largest segment, with a share about 80%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by application?

Ans: And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Who are the main players in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The main players in the Nanomaterial-Based Adjuvants Vaccine Market are Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, Jiangsu Recbio Technology

What are the Application segmentation covered in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The Applications covered in the Nanomaterial-Based Adjuvants Vaccine Market report are Pneumococcus, Human Papilloma Virus, DTaP, Viral Hepatitis TypeA, Viral Hepatitis TypeB, SARS-CoV-2, Others

What are the Type segmentation covered in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The Types covered in the Nanomaterial-Based Adjuvants Vaccine Market report are Aluminium Hydroxides, Aluminium Phosphate, Lipidosome, Others

Recommended Reports

Vaccine Technologies

Disease-Specific Vaccines

Vaccine Market Insights

1 Nanomaterial-Based Adjuvants Vaccine Market Overview
1.1 Product Definition
1.2 Nanomaterial-Based Adjuvants Vaccine by Type
1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Aluminium Hydroxides
1.2.3 Aluminium Phosphate
1.2.4 Lipidosome
1.2.5 Others
1.3 Nanomaterial-Based Adjuvants Vaccine by Application
1.3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Pneumococcus
1.3.3 Human Papilloma Virus
1.3.4 DTaP
1.3.5 Viral Hepatitis TypeA
1.3.6 Viral Hepatitis TypeB
1.3.7 SARS-CoV-2
1.3.8 Others
1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts
1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue 2020-2031
1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales 2020-2031
1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Nanomaterial-Based Adjuvants Vaccine Market Competition by Manufacturers
2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Enter into This Industry
2.8 Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation and Trends
2.8.1 Global Nanomaterial-Based Adjuvants Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue
2.8.3 Global Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nanomaterial-Based Adjuvants Vaccine Market Scenario by Region
3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2020-2031
3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2020-2025
3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2026-2031
3.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2020-2031
3.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2020-2025
3.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2026-2031
3.4 North America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.4.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2031)
3.4.3 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.5.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2031)
3.5.3 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.7.1 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2020-2031)
4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2020-2025)
4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2026-2031)
4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2020-2031)
4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2020-2025)
4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2026-2031)
4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2020-2031)
5.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2020-2025)
5.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2026-2031)
5.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2020-2031)
5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2020-2025)
5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2026-2031)
5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Emergent BioSolutions
6.1.1 Emergent BioSolutions Company Information
6.1.2 Emergent BioSolutions Description and Business Overview
6.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.1.5 Emergent BioSolutions Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 GlaxoSmithKline Biologicals
6.3.1 GlaxoSmithKline Biologicals Company Information
6.3.2 GlaxoSmithKline Biologicals Description and Business Overview
6.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Moderna
6.7.1 Moderna Company Information
6.7.2 Moderna Description and Business Overview
6.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.7.5 Moderna Recent Developments/Updates
6.8 Jiangsu Recbio Technology
6.8.1 Jiangsu Recbio Technology Company Information
6.8.2 Jiangsu Recbio Technology Description and Business Overview
6.8.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.8.5 Jiangsu Recbio Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain Analysis
7.2 Nanomaterial-Based Adjuvants Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process Analysis
7.4 Nanomaterial-Based Adjuvants Vaccine Sales and Marketing
7.4.1 Nanomaterial-Based Adjuvants Vaccine Sales Channels
7.4.2 Nanomaterial-Based Adjuvants Vaccine Distributors
7.5 Nanomaterial-Based Adjuvants Vaccine Customer Analysis
8 Nanomaterial-Based Adjuvants Vaccine Market Dynamics
8.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends
8.2 Nanomaterial-Based Adjuvants Vaccine Market Drivers
8.3 Nanomaterial-Based Adjuvants Vaccine Market Challenges
8.4 Nanomaterial-Based Adjuvants Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GlaxoSmithKline Biologicals
Merck
Pfizer Inc
Novartis
Moderna, Inc
Emergent Biosolutions
Sanofi
Jiangsu Recbio Technology
List of Tables
 Table 1. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) of Key Manufacturers (2020-2025)
 Table 5. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Nanomaterial-Based Adjuvants Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanomaterial-Based Adjuvants Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2020-2025) & (M Doses)
 Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2026-2031) & (M Doses)
 Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025) & (M Doses)
 Table 27. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2026-2031) & (M Doses)
 Table 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025) & (M Doses)
 Table 32. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2026-2031) & (M Doses)
 Table 33. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2020-2025) & (M Doses)
 Table 37. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2026-2031) & (M Doses)
 Table 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025) & (M Doses)
 Table 42. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2026-2031) & (M Doses)
 Table 43. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025) & (M Doses)
 Table 47. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2026-2031) & (M Doses)
 Table 48. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2020-2025)
 Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2026-2031)
 Table 52. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2020-2025)
 Table 61. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2026-2031)
 Table 62. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2026-2031)
 Table 70. Emergent BioSolutions Company Information
 Table 71. Emergent BioSolutions Description and Business Overview
 Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product
 Table 74. Emergent BioSolutions Recent Developments/Updates
 Table 75. Sanofi Company Information
 Table 76. Sanofi Description and Business Overview
 Table 77. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. Sanofi Nanomaterial-Based Adjuvants Vaccine Product
 Table 79. Sanofi Recent Developments/Updates
 Table 80. GlaxoSmithKline Biologicals Company Information
 Table 81. GlaxoSmithKline Biologicals Description and Business Overview
 Table 82. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product
 Table 84. GlaxoSmithKline Biologicals Recent Developments/Updates
 Table 85. Merck Company Information
 Table 86. Merck Description and Business Overview
 Table 87. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Merck Nanomaterial-Based Adjuvants Vaccine Product
 Table 89. Merck Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Pfizer Nanomaterial-Based Adjuvants Vaccine Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Novartis Nanomaterial-Based Adjuvants Vaccine Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. Moderna Company Information
 Table 101. Moderna Description and Business Overview
 Table 102. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Moderna Nanomaterial-Based Adjuvants Vaccine Product
 Table 104. Moderna Recent Developments/Updates
 Table 105. Jiangsu Recbio Technology Company Information
 Table 106. Jiangsu Recbio Technology Description and Business Overview
 Table 107. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product
 Table 109. Jiangsu Recbio Technology Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Nanomaterial-Based Adjuvants Vaccine Distributors List
 Table 113. Nanomaterial-Based Adjuvants Vaccine Customers List
 Table 114. Nanomaterial-Based Adjuvants Vaccine Market Trends
 Table 115. Nanomaterial-Based Adjuvants Vaccine Market Drivers
 Table 116. Nanomaterial-Based Adjuvants Vaccine Market Challenges
 Table 117. Nanomaterial-Based Adjuvants Vaccine Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Nanomaterial-Based Adjuvants Vaccine
 Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Aluminium Hydroxides Product Picture
 Figure 5. Aluminium Phosphate Product Picture
 Figure 6. Lipidosome Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Application: 2024 & 2031
 Figure 10. Pneumococcus
 Figure 11. Human Papilloma Virus
 Figure 12. DTaP
 Figure 13. Viral Hepatitis TypeA
 Figure 14. Viral Hepatitis TypeB
 Figure 15. SARS-CoV-2
 Figure 16. Others
 Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales (2020-2031) & (M Doses)
 Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) & (2020-2031)
 Figure 21. Nanomaterial-Based Adjuvants Vaccine Report Years Considered
 Figure 22. Nanomaterial-Based Adjuvants Vaccine Sales Share by Manufacturers in 2024
 Figure 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest Nanomaterial-Based Adjuvants Vaccine Players: Market Share by Revenue in Nanomaterial-Based Adjuvants Vaccine in 2024
 Figure 25. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2020-2031)
 Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2020-2031)
 Figure 29. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2020-2031)
 Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2020-2031)
 Figure 33. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2020-2031)
 Figure 40. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. China Taiwan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Indonesia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Thailand Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Malaysia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2020-2031)
 Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2020-2031)
 Figure 64. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2020-2031)
 Figure 65. Nanomaterial-Based Adjuvants Vaccine Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Nucleic Acid Vaccine Market Insights Forecast to 2030
Global Mineral based Adjuvants Market Research Report 2024
Global Polymer Nanochemicals Market Research Report 2024
Global Nucleic Vaccine Market Insights Forecast to 2030
Global Biological Vaccines Adjuvants Market Research Report 2025
Veterinary Vaccine Adjuvants Market
Global Intramuscular Vaccine Adjuvants Market Research Report 2025
Animal Vaccine Adjuvant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Copper based Nanoparticles NPs Market Research Report 2025
Global Polymer Nanoparticles PNP Formulation Development Market Research Report 2024
Global Noninvasive Vaccination Market Research Report 2025
Global Non invasive Vaccine Market Research Report 2025
Immunostimulatory Adjuvants Market
Global Noninvasive Delivery Vaccine Market Research Report 2025
Global Oral Vaccine Adjuvants Market Research Report 2025
Nanocarrier Based Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vaccine Particulate Adjuvants Market Research Report 2025
Global Subcutaneous Vaccine Adjuvants Market Research Report 2025
Global Aluminum Nanoparticles Market Research Report 2024
Nucleic Acid Delivery Excipients Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions